Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Four On Japanese Panel Say AstraZeneca Paid After Iressa Decision

This article was originally published in PharmAsia News

Executive Summary

Another physician has admitted in a Japanese court case that he received more than $166,000 from AstraZeneca after sitting on a board that endorsed the drug maker's Iressa (gefitinib). The former professor of a private university was among 10 doctors on the board, four of whom have testified so far they received payments. The Tokyo trial involves a suit against the firm and the government brought by families of patients who died of side effects after taking the lung cancer drug. The Ministry of Health, Labor and Welfare has asked the Japan Lung Cancer Society to re-evaluate Iressa's safety. (Click here for more

Related Content

Japan Sets Conflict Rules For Outside Drug Reviewers



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts